The association between therapeutic plasma exchange and the risk of mortality among patients critically ill with COVID-19: a meta-analysis

Author:

Wardhani Shinta OktyaORCID,Fajar Jonny KaruniaORCID,Soegiarto GatotORCID,Wulandari Laksmi,Maliga Helnida AnggunORCID,Ilmawan MuhammadORCID,Merysa Risna,Simamora Arlentina Bentivolia,Aini Qurrata,Noviantari Komang,Lestari Ayu Widya,Harnila Maria Yoheni,Syafi'i Imam,Djianzonie Jane Andrea Christiano,Siagian Nenci,Nining Sri,Hanim Risyda Zakiyah,Wahyuni Wahyuni,Aulia Fitri,Juliansyah Juliansyah,Mahmud Reflin,Tamara Fredo,Mahendra Aditya IndraORCID,Wowor Amanda Cininta,Baladraf Fikri,Hadinata Ponda Hernest,Ikkeputri Adhityari,Nadya Hana,Kartini Dessy Aprilia,Husnah Milda,Nainu FirzanORCID,Harapan HarapanORCID

Abstract

Background: Cytokine storm has been widely known to contribute to the development of the critical condition in patients with coronavirus disease 2019 (COVID-19), and studies had been conducted to assess the potential aspect of cytokine storm elimination by performing therapeutic plasma exchange (TPE). However, contradictory findings were observed. The objective of this study was to assess the association between TPE and the reduction of mortality of critically ill COVID-19 patients. Methods: A meta-analysis was conducted by collecting data from PubMed, Scopus, and Web of Science. Data on the mortality rate of critically ill COVID-19 patients treated with TPE plus standard of care and that of patients treated with standard of care alone were analyzed using a Z test. Results: We included a total of four papers assessing the association between TPE and the risk of mortality among critically ill COVID-19 patients. Our findings suggested that critically ill COVID-19 patients treated with TPE had lower risk of mortality compared to those without TPE treatment. Conclusion: Our study has identified the potential benefits of TPE in reducing the risk of mortality among critically ill COVID-19 patients.

Publisher

F1000 Research Ltd

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3